Taiwan Liposome Company (TLC), a clinical-stage pharmaceutical company engaged in commercialization of lipid-based pharmaceutical products, has filed a proposal for a Nasdaq IPO, the company announced on February 17.
Register now to enjoy 3 free articles per month,
or log in to continue reading.
Stay informed with complimentary articles each month
Gain access to our exclusive newsletters delivered directly to your inbox
Be the first to know about all our summits!
Already a Subscriber? Log in
